证券代码：002286 证券简称：保龄宝 编号：2021-005 | --- | --- | --- | |-----------------------------|------------------------|-----------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 | □分析师会议 | | 类别 | | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | | 参与单位名称及 | | 富国基金：李元博、沈衡、徐哲琪 | | 人员姓名 | 天风证券：王聪 | | | | | | | 时间 2021 年 | 12 月 14 日 | 16:00-17:00 | | 地点 电话会议 | | | | 上市公司接待人 员姓名 | 张国刚、李发财、张锋锋 | | | | Q A | ：今年和明年赤藓糖醇的订单情况，客户增长情况 ：保龄宝的客户群体比较稳定，在饮 ...

Group 1: Industry Overview - The domestic health issues include sub-health problems, aging, and chronic diseases related to gut health, presenting market opportunities for the company [2] - The sugar-free product market in China is expected to grow significantly, with sugar-free products currently accounting for less than 5% of the market [2][3] - The functional sugar industry is experiencing rapid growth, with the market size projected to reach CNY 227.4 billion by 2025, doubling in five years [3] Group 2: Company Strengths - The company has a complete industrial chain for functional sugar manufacturing, providing a wide range of products and services [3] - The company has established a robust quality management system for functional sugars, validated by over 20 years of customer experience [3][6] - The company’s product structure includes a pyramid of high, medium, and low-end products, enhancing its competitive edge [3] Group 3: Performance and Targets - The company aims for a revenue of CNY 3.75 billion in 2022, representing a 44% year-on-year growth, and a net profit of CNY 260 million, a 73% increase [3] - For 2023, the revenue target is CNY 4.5 billion, with a 20% growth, and a net profit target of CNY 340 million, a 30% increase [3] Group 4: Future Strategies - The company plans to expand production capacity for erythritol and allulose, with projects already underway [4] - The company will focus on refining management practices to achieve innovation, cost reduction, and collaborative efficiency [4] - The company aims to explore new markets and develop differentiated application solutions to enhance revenue [4] Group 5: Product Development Focus - The company identifies isomalto-oligosaccharides as a key product with significant market potential, aiming to replace maltodextrin in beverages [5] - Resistant dextrin is expected to see rapid demand growth, with plans for technical upgrades to meet market needs [5] - Allulose is anticipated to gain approval for use in food and beverages in the EU by 2022, with domestic demand expected to rise by 2023 [5][6] Group 6: Market Dynamics - Erythritol accounted for approximately 25% of the company's revenue in 2021, with demand expected to reach 300,000 tons this year [6] - The market for erythritol is projected to grow to 500,000 tons in the next 3-5 years, driven by expanding applications [6] - The competitive landscape for erythritol includes barriers such as customer certification processes and quality management systems [6][7]

证券代码：002286 证券简称：保龄宝 保龄宝生物股份有限公司投资者关系活动记录表 编号：2022-001 | --- | --- | --- | |----------------|--------------------------------------------|-------------------------------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 | □分析师会议 | | 类别 | | √媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 □其他 | | | 参与单位名称及 | 证券时报：李师胜、黄翔； | | | 人员姓名 | 东北证券：唐凯、陈渊文； | | | | 中信证券：刘煜坤、顾训丁； | | | | 广发证券：何雄、李博； 安信证券 : 张汪强。 | | | | | | | 时间 2022 | 年 1 月 10 日、 | 2022 年 1 月 11 日、 2022 年 1 月 13 日 | | | 地点 公司办公楼、电话会议 | | | 上市公司接待人 ...

证券代码：002286 证券简称：保龄宝 保龄宝生物股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-008 证券代码：002286 证券简称：保龄宝 保龄宝生物股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

| --- | --- | --- | --- | |------------------|--------------------------------------------|----------------------------------------------------------------------|------------------------------| | | | | | | 证券简称：保龄宝 | 证券代码： | 002286 | 公告编号： 2022-074 | | | | 保龄宝生物股份有限公司 | | | | 关于参加山东辖区上市公司 | 2022 | 年度投资者网上集 | | | | 体接待日活动的公告 | | | | | 公司董事会及全体成员保证公告内容的真实、准确和完整，不存在虚假记录、 | | | | 误导性陈述或者重大遗漏。 | | | | | | 为进一步加强与广大投资者的沟通交流，保龄宝生物股份有限公司（以下简 | | | 称 " 公司 " | ）将于 2022年11月16 日（星期三） | 14:00 | — 16:00 参加由山东证监局、 | | | | ...

证券代码： 002286 证券简称：保龄宝 保龄宝生物股份有限公司投资者关系活动记录表 编号：2022-010 | --- | --- | --- | |----------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

保龄宝生物股份有限公司 2022 年第三季度报告 证券代码：002286 证券简称：保龄宝 公告编号：2022-067 保龄宝生物股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 4.受国际、国内疫情反复，大宗商品价格上涨，消费低迷，部分产品竞争加剧等不利因素影响，报告期内，公司业绩出 现波动，剔除赤藓糖醇产品价格波动影响，公司盈利能力仍保持稳定增长。公司正围绕高端化，功能化、差异化，数字 化四化目标，实现转型升级。 在收入增加战略方面，一是通过创新解决方案引领，扩大新市场，新产品和新客户的收入规模；二是通过强化与现 有客户的关系而增加现有客户的销售，包括组合销售，多种产品和服务，为客户提供一体化解决方案。 在 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,382,780,708.23, representing a 9.61% increase compared to ¥1,261,506,868.39 in the same period last year [23]. - The net profit attributable to shareholders was ¥90,752,005.19, a 40.60% increase from ¥64,545,330.64 year-on-year [23]. - The net profit after deducting non-recurring gains and losses was ¥85,368,968.55, up 68.96% from ¥50,525,838.51 in the previous year [23]. - The basic earnings per share increased by 41.18% to ¥0.24 from ¥0.17 in the same period last year [23]. - The company achieved a total revenue of 1.383 billion CNY, representing a year-on-year growth of 9.61% [57]. - The net profit attributable to shareholders reached 90.75 million CNY, marking a year-on-year increase of 40.60% [57]. - The gross profit margin for the first half of 2022 was reported at 42.76%, indicating strong operational efficiency [76]. - The company's net profit margin for the first half of 2022 was 5.8%, indicating a stable profitability level [199]. Cash Flow and Liquidity - The company reported a net cash flow from operating activities of -¥78,219,756.47, a significant decrease of 136.74% compared to ¥212,883,308.91 in the previous year [23]. - The company's cash and cash equivalents decreased by 378.01%, totaling ¥-73,535,747.06, primarily due to increased payments for raw materials and project costs [58]. - The company's cash and cash equivalents decreased from 585,440,493.40 CNY at the beginning of the year to 375,154,746.34 CNY by June 30, 2022, a decline of approximately 36% [179]. - The ending balance of cash and cash equivalents was 333,354,746.34 CNY as of the end of the first half of 2022, compared to 271,502,006.73 CNY at the end of the first half of 2021 [194]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,009,685,058.70, a slight decrease of 0.64% from ¥3,028,995,791.18 at the end of the previous year [23]. - The company's long-term borrowings increased by 1,087.84% to ¥231,955,198.89, primarily due to new project financing [60]. - Current liabilities totaled ¥830,706,883.68, a decrease from ¥1,119,839,668.47 at the start of the year, indicating a reduction of approximately 25.8% [181]. - The total liabilities at the end of the reporting period were 1.8 billion yuan, representing a 3.7% increase from the previous year [200]. Business Operations and Strategy - The company continues to focus on enzyme engineering and fermentation engineering, maintaining a strong position in the functional sugar industry with over 90 different specifications of functional food ingredients [30]. - The company has developed a comprehensive product structure covering high, medium, and low categories of functional sugars, including functional oligosaccharides, dietary fibers, and functional sugar alcohols [32]. - The company is a strategic partner for many food and beverage enterprises and is a key player in the national "Public Nutrition Improvement Microecology Project" [30]. - The company has established a complete industrial chain for the production of erythritol, which has gained wide recognition in both domestic and international markets [87]. - The company is focusing on high-tech, high-margin, and high-value-added products, with traditional products like glucose syrup and maltodextrin seeing steady margin improvements [56]. Research and Development - The company is actively investing in R&D for new technologies, with a budget allocation of 1,880 million for innovation initiatives [76]. - The company plans to enhance its research and development investment in functional sugars to improve product quality and application solutions [87]. - The company has implemented a digital upgrade in its production processes, with its "medicinal sugar workshop" recognized as a digital workshop by the Shandong Provincial Department of Industry and Information Technology [131]. Environmental and Social Responsibility - The company has maintained stable operation of its environmental protection facilities, achieving compliance with pollutant discharge standards [100]. - The company has implemented measures to reduce carbon emissions, although specific results were not detailed in the report [111]. - The company emphasizes its mission of "creating a better life through biotechnology," focusing on economic, social, and ecological benefits [112]. - The company has actively participated in social responsibility initiatives, promoting green development and sustainable practices [112]. Risk Management - The management has highlighted potential risks and corresponding mitigation strategies in the report [6]. - The company has implemented a hedging strategy to mitigate raw material price fluctuations, particularly for corn and corn starch, which are subject to significant market volatility [84]. - The company aims to reduce the impact of raw material price increases on profit margins by improving production processes and exploring new procurement models [84]. Shareholder and Governance - The company has not engaged in any major asset or equity sales during the reporting period, maintaining its asset structure [82]. - The company has not utilized any fundraising during the reporting period, indicating stable financial management [81]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period, indicating financial integrity [136].

Financial Performance - The company's revenue for Q1 2022 was CNY 657,767,709.68, representing an increase of 18.54% compared to CNY 554,900,133.35 in the same period last year[3] - Net profit attributable to shareholders reached CNY 42,723,700.71, a significant increase of 383.94% from CNY 8,828,328.31 in the previous year[3] - The net profit after deducting non-recurring gains and losses was CNY 39,345,780.14, up 585.62% from CNY 5,738,709.86 year-on-year[3] - Basic and diluted earnings per share were both CNY 0.11, reflecting a 450.00% increase from CNY 0.02 in the previous year[3] - Total operating revenue for the current period reached ¥657,767,709.68, an increase from ¥554,900,133.35 in the previous period[16] - Net profit for the current period was ¥42,723,700.71, compared to ¥8,828,328.31 in the previous period, reflecting a significant increase[18] - The total comprehensive income for the current period was ¥29,784,691.74, compared to ¥7,975,787.69 in the previous period[19] - The company reported a basic and diluted earnings per share of ¥0.11, up from ¥0.02 in the previous period[19] Cash Flow and Liquidity - The company's cash flow from operating activities showed a net outflow of CNY 136,105,401.07, a decrease of 392.90% compared to a net inflow of CNY 46,468,413.92 in the same period last year[3] - The company reported a net cash flow from operating activities of -¥136,105,401.07, a decline from a positive cash flow of ¥46,468,413.92 in the prior period[22] - Cash inflow from operating activities was ¥750,203,392.85, an increase from ¥633,224,145.16 in the previous period[20] - The company's cash and cash equivalents decreased by 35.58% to CNY 377,116,103.66 due to increased payments for raw materials[6] - Cash and cash equivalents at the end of the period totaled ¥346,066,103.66, compared to ¥267,784,546.92 at the end of the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,914,407,619.13, down 3.78% from CNY 3,028,995,791.18 at the end of the previous year[3] - Total assets decreased to ¥2,914,407,619.13 from ¥3,028,995,791.18, a decline of approximately 3.8%[15] - Total liabilities decreased to ¥1,066,584,375.80 from ¥1,215,764,108.09, a reduction of about 12.3%[14] - The company's retained earnings increased to ¥573,412,669.35 from ¥530,688,968.64, showing an increase of approximately 8%[15] - The total equity attributable to the parent company was ¥1,847,823,243.33, up from ¥1,813,231,683.09, reflecting a growth of about 1.9%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 40,936[9] - The top shareholder, Beijing Yongyu Investment Management Co., Ltd., holds 12.71% of shares, totaling 47,273,390 shares[10] Expenses - The company reported a significant increase in sales expenses by 33.35% to CNY 9,186,432.63, mainly due to higher salaries for sales personnel[6] - The company incurred research and development expenses of ¥1,879,430.38, slightly up from ¥1,760,718.02 in the previous period[16] Borrowings and Financing - Long-term borrowings increased by 792.83% to CNY 174,347,543.03, attributed to project financing and medium to long-term loans[6] - The company reported a short-term loan balance of ¥420,419,471.56, an increase from ¥369,178,398.38 at the beginning of the year[14] - The company raised ¥340,111,933.86 from financing activities, compared to ¥133,000,000.00 in the previous period[22] Accounts Receivable and Inventory - Accounts receivable increased to ¥313,411,937.67 from ¥284,293,463.48, reflecting a growth of approximately 10%[13] - Inventory at the end of the reporting period was ¥340,650,286.07, compared to ¥285,092,988.97 at the beginning of the year, indicating an increase of about 19.5%[13]